Johnson & Johnson $JNJ Shares Sold by EFG Asset Management Americas Corp.

EFG Asset Management Americas Corp. decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 44.1% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 12,113 shares of the company’s stock after selling 9,551 shares during the quarter. EFG Asset Management Americas Corp.’s holdings in Johnson & Johnson were worth $1,850,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. W.H. Cornerstone Investments Inc. raised its holdings in shares of Johnson & Johnson by 0.7% during the second quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company’s stock valued at $1,206,000 after buying an additional 58 shares during the last quarter. Greenup Street Wealth Management LLC increased its position in Johnson & Johnson by 3.1% in the 2nd quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company’s stock valued at $309,000 after acquiring an additional 60 shares during the period. Ellis Investment Partners LLC raised its stake in Johnson & Johnson by 0.7% during the 2nd quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock valued at $1,307,000 after acquiring an additional 62 shares in the last quarter. Cypress Wealth Services LLC grew its stake in shares of Johnson & Johnson by 0.9% in the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock worth $1,013,000 after purchasing an additional 62 shares in the last quarter. Finally, Horizon Bancorp Inc. IN increased its holdings in shares of Johnson & Johnson by 11.2% during the second quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company’s stock valued at $97,000 after purchasing an additional 64 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Up 1.5%

JNJ stock opened at $203.04 on Thursday. The company’s 50 day simple moving average is $187.24 and its 200-day simple moving average is $170.99. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $203.48. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The firm has a market capitalization of $489.18 billion, a P/E ratio of 19.60, a P/E/G ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is 50.19%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on JNJ. Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. JPMorgan Chase & Co. upped their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Bank of America lifted their price target on Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a research report on Wednesday, October 15th. Loop Capital set a $190.00 target price on Johnson & Johnson in a research note on Wednesday, October 22nd. Finally, Stifel Nicolaus lifted their target price on Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a report on Wednesday, October 15th. Four analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $201.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.